ATE486890T1 - Ephb-rezeptorbindende peptide - Google Patents

Ephb-rezeptorbindende peptide

Info

Publication number
ATE486890T1
ATE486890T1 AT06733967T AT06733967T ATE486890T1 AT E486890 T1 ATE486890 T1 AT E486890T1 AT 06733967 T AT06733967 T AT 06733967T AT 06733967 T AT06733967 T AT 06733967T AT E486890 T1 ATE486890 T1 AT E486890T1
Authority
AT
Austria
Prior art keywords
receptor binding
binding peptides
peptides
ephb receptor
patients
Prior art date
Application number
AT06733967T
Other languages
English (en)
Inventor
Elena Pasquale
Mitchell Koolpe
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Application granted granted Critical
Publication of ATE486890T1 publication Critical patent/ATE486890T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
AT06733967T 2005-01-27 2006-01-26 Ephb-rezeptorbindende peptide ATE486890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64785205P 2005-01-27 2005-01-27
PCT/US2006/002923 WO2006081418A2 (en) 2005-01-27 2006-01-26 Ephb receptor-binding peptides

Publications (1)

Publication Number Publication Date
ATE486890T1 true ATE486890T1 (de) 2010-11-15

Family

ID=36606084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733967T ATE486890T1 (de) 2005-01-27 2006-01-26 Ephb-rezeptorbindende peptide

Country Status (10)

Country Link
US (2) US7582438B2 (de)
EP (1) EP1841790B1 (de)
JP (1) JP2008528614A (de)
KR (1) KR20070118230A (de)
CN (1) CN101146822A (de)
AT (1) ATE486890T1 (de)
AU (1) AU2006208068B2 (de)
CA (1) CA2595892A1 (de)
DE (1) DE602006017964D1 (de)
WO (1) WO2006081418A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553963A4 (de) 2002-09-24 2006-05-03 Burnham Inst NEUE MITTEL ZUR MODULIERUNG DER EPH-REZEPTOR-AKTIVITûT
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
ATE486890T1 (de) 2005-01-27 2010-11-15 Burnham Inst Ephb-rezeptorbindende peptide
CA2644743C (en) 2006-03-08 2015-05-19 Waldemar Debinski Soluble monomeric ephrin a1
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
JP2009221107A (ja) * 2006-05-24 2009-10-01 Aqumen Biopharmaceuticals Kk エフリンｂ２の活性を高めるペプチド，その塩，医薬用組成物，治療用キット
CA2662684A1 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
WO2008060481A1 (en) * 2006-11-10 2008-05-22 Parker College Of Chiropractic Method for treating chronic pain
US8232085B2 (en) 2007-03-14 2012-07-31 Bionsil S.R.L. Isoform of bruton's tyrosine kinase (BTK) protein
WO2008156642A1 (en) * 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
WO2010108122A1 (en) * 2009-03-20 2010-09-23 Sanford-Burnham Medical Research Institute Targeted delivery of chemotherapeutic agents
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
WO2013106824A1 (en) * 2012-01-13 2013-07-18 Board Of Regents, The University Of Texas System Epherin receptor targeting agents
WO2013108869A1 (ja) * 2012-01-20 2013-07-25 国立大学法人岡山大学 がんの治療又は予防剤
CN105694891B (zh) * 2015-12-30 2018-01-23 深圳先进技术研究院 一种用于荧光寿命编码的量子点及其荧光寿命编码方法
CN105906691B (zh) * 2016-07-05 2019-09-13 珠海诺贝尔国际生物医药研究院有限公司 一种Eph激酶多肽抑制剂及其应用
CN106153920B (zh) * 2016-07-25 2018-04-27 四川大学华西医院 一种肺癌筛查试剂盒
CN114096848A (zh) * 2019-05-08 2022-02-25 得克萨斯州大学系统董事会 治疗性肽

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333777C (en) 1988-07-01 1995-01-03 Randy M. Berka Aspartic proteinase deficient filamentous fungi
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
EP0669929B1 (de) 1992-11-13 2007-01-03 Immunex Corporation Elk ligand, ein cytokin
IL107599A0 (en) 1992-11-13 1994-02-27 Amgen Inc Eck receptor ligands
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5864020A (en) 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
WO1996010911A1 (en) 1994-10-05 1996-04-18 Immunex Corporation Cytokine designated lerk-6
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US5798448A (en) 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
DE69532857T2 (de) 1994-10-27 2005-04-28 Genentech Inc., San Francisco Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor
EP0871702B1 (de) 1994-12-06 2005-05-25 Immunex Corporation Cytokin lerk-7
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
US6001964A (en) 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
WO1997036919A2 (en) 1996-03-21 1997-10-09 Immunex Corporation Cytokine designated lerk-8
EP0864956A3 (de) * 1997-03-12 1999-03-31 Texas Instruments Incorporated Spannungsregler mit niedrigem Spannungsabfall
WO1999008696A1 (en) 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
CA2326408A1 (en) 1998-03-02 1999-09-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Epitope peptides immunogenic against streptococcus pneumoniae
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
ES2237115T5 (es) 1998-06-24 2008-05-16 Innogenetics N.V. Particulas de proteinas de la envoltura del hcv: uso para la vacunacion.
WO2000030673A1 (en) 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
AU1764200A (en) 1998-12-18 2000-07-12 Mount Sinai Hospital Corporation Three dimensional structure of a sterile alpha motif domain
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
WO2003004057A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
EP1553963A4 (de) * 2002-09-24 2006-05-03 Burnham Inst NEUE MITTEL ZUR MODULIERUNG DER EPH-REZEPTOR-AKTIVITûT
JP2006521111A (ja) * 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP2006524693A (ja) 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
ATE486890T1 (de) 2005-01-27 2010-11-15 Burnham Inst Ephb-rezeptorbindende peptide
CA2662684A1 (en) 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof

Also Published As

Publication number Publication date
US20060177452A1 (en) 2006-08-10
EP1841790B1 (de) 2010-11-03
WO2006081418A2 (en) 2006-08-03
EP1841790A2 (de) 2007-10-10
CA2595892A1 (en) 2006-08-03
CN101146822A (zh) 2008-03-19
JP2008528614A (ja) 2008-07-31
US7582438B2 (en) 2009-09-01
US7999069B2 (en) 2011-08-16
KR20070118230A (ko) 2007-12-14
AU2006208068B2 (en) 2011-08-04
DE602006017964D1 (de) 2010-12-16
US20100183510A1 (en) 2010-07-22
WO2006081418A3 (en) 2006-12-07
HK1108702A1 (en) 2008-05-16
AU2006208068A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
ATE486890T1 (de) Ephb-rezeptorbindende peptide
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
MY169272A (en) Her2 antibody composition
EA201100923A1 (ru) Антитела человека против тканевого фактора
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
CL2008002886A1 (es) Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
DK1957539T3 (da) Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DE602005026789D1 (de) Le
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
DK2227243T3 (da) Farmaceutisk sammensætning til behandling af obesitet relaterede sygdomme, omfattende et insulinotropisk peptidkonjugat
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
IL189452A0 (en) Therapy with cd4 binding peptides and radiation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties